Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

Mucus & Phlegm relief extra strength

Canada Type II Ongoing · initiated 2025-12-05

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product, or for any health conce…

PMS-ZOLPIDEM ODT 10mg

Canada Type II Ongoing · initiated 2025-12-03

Packaging. Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concern…

ERYTHROMYCIN OPHTHALMIC OINTMENT USP

Canada Type II Ongoing · initiated 2025-12-01

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Nitrous Oxide Chargers

Canada Type I Ongoing · initiated 2025-11-28

Product safety. Do not inhale nitrous oxide products for recreational purposes.Seek immediate medical attention from a health care professional (physician, nurs…

Winder Laboratories, LLC

US Class III Ongoing · initiated 2025-11-26

Correct Labeled Product Mispack-Size stated on carton label did not match the size of the bottle in the carton.

Golden State Medical Supply Inc.

US Class II Ongoing · initiated 2025-11-26

Presence of Foreign Tablets/Capsules

SOMERSET THERAPEUTICS LLC

US Class III Ongoing · initiated 2025-11-26

Subpotent product:out of specification assay results observed during long term stability testing.

SOMERSET THERAPEUTICS LLC

US Class III Ongoing · initiated 2025-11-26

Subpotent product:out of specification assay results observed during long term stability testing.

SOMERSET THERAPEUTICS LLC

US Class III Ongoing · initiated 2025-11-26

Subpotent product:out of specification assay results observed during long term stability testing.

SUN PHARMACEUTICAL INDUSTRIES INC

US Class III Ongoing · initiated 2025-11-26

Failed Impurities/Degradation: Out of Specification results for Total Impurities and for Assay.

MapleLife Magnesium Bisglycinate 200mg

Canada Type III Ongoing · initiated 2025-11-26

Product safety. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health con…

Breckenridge Pharmaceutical, Inc.

US Class II Ongoing · initiated 2025-11-24

CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit

Breckenridge Pharmaceutical, Inc.

US Class II Ongoing · initiated 2025-11-24

CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit

Extra Strength Ibuprofen Liquid Gel Capsules 400mg

Canada Type II Ongoing · initiated 2025-11-24

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Glenmark Pharmaceuticals Inc., USA

US Class III Ongoing · initiated 2025-11-21

Cross Contamination with Other Products: Testing of reserve samples showed presence of traces of ezetimibe

Fagron Compounding Services

US Class II Ongoing · initiated 2025-11-20

Incorrect Product Formulation

PMS-QUETIAPINE 50mg

Canada Type III Ongoing · initiated 2025-11-20

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

JAMP-Risperidone 0.25mg

Canada Type III Ongoing · initiated 2025-11-19

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Glenmark Pharmaceuticals Inc., USA

US Class III Ongoing · initiated 2025-11-18

Cross Contamination with Other Products

Preferred Pharmaceuticals, Inc.

US Class II Ongoing · initiated 2025-11-17

Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling…

Cipla USA, Inc.

US Class II Ongoing · initiated 2025-11-14

CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.

Cipla USA, Inc.

US Class II Ongoing · initiated 2025-11-14

CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.

Cipla USA, Inc.

US Class II Ongoing · initiated 2025-11-14

CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.

Lupin Pharmaceuticals Inc.

US Class II Ongoing · initiated 2025-11-13

Failed impurities/degradation specifications: out of specification results for Ganirelix acetate acrylic acid adduct impurity.

Septodont Products

Canada Type II Ongoing · initiated 2025-11-13

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…